Novan, Inc. is a Durham, North Carolina-based medical dermatology company founded in 2006 and publicly traded on Nasdaq (NOVN). The company develops therapeutic products for skin diseases, including its lead candidate SB206 for molluscum contagiosum. Through its 2022 acquisition of EPI Health, LLC, Novan operates a commercial platform marketing prescription drugs for rosacea, plaque psoriasis, and acne. The company maintains a 20,000-square-foot headquarters and manufacturing facility, employing 39 staff members.
